Serial 3T MRI in early Parkinson’s to validate PD progression markers: Rationale and MRI analysis plan for nigral depigmentation at baseline, 6- and 12-months’ follow-up
Publication Date
November 2, 2023
Creators
Description
Access to these files may be requested. Please contact Dr Xing at You.Xing@nottingham.ac.uk. While NM-MRI has shown promise in diagnosing PD, its potential as a progression marker, particularly in the early stages when disease-modifying treatments are most effective, remains relatively unexplored.
Our InsIghtPD study focuses on evaluating the substantia nigra, primarily looking at nigral depigmentation at baseline, 6- and 12-months’ follow-up. Secondary metrics, such as free water, kurtosis, and susceptibility, are also examined. Additionally, the study explores other whole brain metrics with potential as progression markers. The goal is to understand the minimal detectable change in these MRI metrics during the early clinical phase of PD. Furthermore, the study seeks to differentiate PD-related pathological changes from the effects of natural aging, which is critical for accurately assessing disease progression.
Subjects (MeSH)
Subjects
Subjects (JACS)
Subjects (LC)
Divisions
University of Nottingham, UK Campus::Faculty of Medicine and Health Sciences::School of Medicine
Data type
Protocol
Funders
Funders
Weston Brain Institute, Weston Family Foundation
National Institute for Health Research, Nottingham Biomedical Research Centre
Grant Number
UB190188
Data collection method
Data analysis plan
Resource languages
English
Publisher
The University of Nottingham
Date Issued
November 2, 2023
Except where otherwise noted, this item's license is described as
File(s)![Thumbnail Image]()
Name
InsightPD_first_data_analysis_protocol.pdf
Description
rationale and analysis plan
Size
201.28 KB
Format
Adobe PDF
Checksum (MD5)
156295aa5935fa7d04778ae8d14fbfdb